This HTML5 document contains 70 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n21http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00118/identifier/chemspider/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00118/identifier/chebi/
n18http://bio2rdf.org/drugbank:
n17http://linked.opendata.cz/resource/drugbank/drug/DB00118/identifier/wikipedia/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00118/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n13http://linked.opendata.cz/resource/drugbank/drug/DB00118/identifier/kegg-compound/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00118/identifier/pdb/
n7http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00118/identifier/pubchem-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n22http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n20http://linked.opendata.cz/ontology/mesh/
n24http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/
n3http://linked.opendata.cz/ontology/drugbank/
n16http://www.drugs.com/cdi/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00118/identifier/pubchem-substance/
n5http://linked.opendata.cz/resource/drugbank/property/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00118/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB00118
rdf:type
n3:Drug
n3:description
Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed)
n3:generalReferences
# Finkelstein JD, Martin JJ: Homocysteine. Int J Biochem Cell Biol. 2000 Apr;32(4):385-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10762063 # Fodinger M, Horl WH, Sunder-Plassmann G: Molecular biology of 5,10-methylenetetrahydrofolate reductase. J Nephrol. 2000 Jan-Feb;13(1):20-33. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10720211 # Roje S: S-Adenosyl-L-methionine: beyond the universal methyl group donor. Phytochemistry. 2006 Aug;67(15):1686-98. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16766004 # Loenen WA: S-adenosylmethionine: jack of all trades and master of everything? Biochem Soc Trans. 2006 Apr;34(Pt 2):330-3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16545107 # Chiang PK, Gordon RK, Tal J, Zeng GC, Doctor BP, Pardhasaradhi K, McCann PP: S-Adenosylmethionine and methylation. FASEB J. 1996 Mar;10(4):471-80. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8647346
n3:group
nutraceutical approved
n3:indication
S-Adenosylmethionine (SAMe) is used as a drug in Europe for the treatment of depression, liver disorders, fibromyalgia, and osteoarthritis. It has also been introduced into the United States market as a dietary supplement for the support of bone and joint health, as well as mood and emotional well being.
owl:sameAs
n7:DB00118 n18:DB00118
dcterms:title
S-Adenosylmethionine
adms:identifier
n9:46505280 n10:SAM n11:34756 n12:DB00118 n13:C00019 n17:S-Adenosylmethionine n19:PA164754994 n23:15414 n25:31983
n3:mechanismOfAction
S-Adenosylmethionine (SAMe) is a natural substance present in the cells of the body. It is a direct metabolite of the essential amino acid L-methionine. SAMe plays a crucial biochemical role in the body by donating a one-carbon methyl group in a process called transmethylation. SAMe, formed from the reaction of L-methionine and adenosine triphosphate catalyzed by the enzyme S-adenosylmethionine synthetase, is the methyl-group donor in the biosynthesis of both DNA and RNA nucleic acids, phospholipids, proteins, epinephrine, melatonin, creatine and other molecules.
n3:packager
n4:271B46ED-363D-11E5-9242-09173F13E4C5 n4:271B46EE-363D-11E5-9242-09173F13E4C5
n3:synonym
Acylcarnitine [1-(Adenin-9-yl)-1,5-dideoxy-beta-D-ribofuranos-5-yl][(3S)-3-amino-3-carboxypropyl](methyl)sulfonium (3S)-5'-[(3-amino-3-Carboxypropyl)methylsulfonio]-5'-deoxyadenosine, inner salt S-adenosyl-L-methionine AdoMet SAMe S-Adenosylmethionine S-(5'-Deoxyadenosin-5'-yl)-L-methionine SAM
n3:toxicity
Irritating to mucus membranes and upper respiratory tract. Can cause CNS depression.
n3:salt
n3:synthesisReference
Takayasu Tsuchida, Fumihiro Yoshinaga, Shinji Okumura, "Method for producing S-adenosylmethionine or methylthioadenosine by yeast." U.S. Patent US3962034, issued November, 1971.
n20:hasConcept
n21:M0019322
foaf:page
n16:s-adenosylmethionine.html n24:sad_0231.shtml
n3:IUPAC-Name
n5:271B46F6-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B46FC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B46FB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B46F8-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B46F9-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B46FA-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B46F4-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B46F2-363D-11E5-9242-09173F13E4C5 n5:271B46F5-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B46F3-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n5:271B4702-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B4703-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B46FD-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B46FE-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B4700-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B46FF-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B4701-363D-11E5-9242-09173F13E4C5
n3:absorption
S-Adenosylmethionine is absorbed from the small intestine following oral intake. As absorption is affected by food, it is best to take on an empty stomach. Bioavailability is low following oral intake.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
29908-03-0
n3:category
n3:containedIn
n22:271B46F1-363D-11E5-9242-09173F13E4C5 n22:271B46EF-363D-11E5-9242-09173F13E4C5 n22:271B46F0-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B4708-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n5:271B470C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B470A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B470B-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B4707-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B4706-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B4709-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B46F7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B4704-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B4705-363D-11E5-9242-09173F13E4C5